WHO Names Promising Drugs & Vaccines for Ebola Outbreak Control
Matichon•International•
Full article content is available on the original source.
Source: Matichon (Original)
Key Quotes
"WHO stated that the vaccine should not be used outside the lab due to insufficient evidence of efficacy against the Bundibugyo Ebola virus strain."
WHO ระบุว่าวัคซีนดังกล่าวไม่ควรนำไปใช้นอกห้องแลบ เพราะยังไม่มีหลักฐานมากพอเกี่ยวกับประสิทธิภาพต่อไวรัสอีโบลาสายพันธุ์บุนดิบูเกียว
Key Entities
Organization
The international public health agency identifying promising treatments and vaccines for the Bundibugyo Ebola virus.
Mapp Biopharmaceutical
The developer of the investigational drug MBP134.
Regeneron
The developer of the investigational drug Maftivimab.
Gilead Science
The company that developed the Antiviral Remdesivir.
International AIDS Vaccine Initiative
The developer of the promising rVSV Bundibugyo vaccine candidate.
One of the institutions developing the ChAdOx1 Bundibugyo vaccine candidate.
One of the institutions developing the ChAdOx1 Bundibugyo vaccine candidate.
Merck
The company that developed the Ervebo vaccine.
Law
MBP134
An investigational drug identified by the WHO for potential use against the Bundibugyo Ebola virus.
Maftivimab
An investigational drug identified by the WHO for potential use against the Bundibugyo Ebola virus, sent to DR Congo.
Antiviral Remdesivir
An investigational drug identified by the WHO as important for preventing infection in individuals exposed to the Bundibugyo Ebola virus.
rVSV Bundibugyo
A vaccine candidate identified as highly effective in a single dose for the Bundibugyo Ebola virus, developed by International AIDS Vaccine Initiative.
ChAdOx1 Bundibugyo
A vaccine candidate for the Bundibugyo Ebola virus being developed by the University of Oxford and the Serum Institute of India.
Ervebo
The only Ebola vaccine with a certification for use, currently being studied by the WHO for effectiveness against the Bundibugyo strain.
Place
A country where the Bundibugyo Ebola virus is spreading and where Maftivimab has been sent for potential use.
DR Congo(ดีอาร์คองโก)
An abbreviation for the Democratic Republic of Congo, where the Bundibugyo Ebola virus is spreading.
A country where the Bundibugyo Ebola virus is spreading, lacking sufficient evidence for the use of the Ervebo vaccine.